Astellas Pharma Inc (ALPMY)
Company Info
| ISIN | US04623U1025 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Highlights
| Market Cap | $20.59B |
|---|---|
| EPS (TTM) | $0.08 |
| PE Ratio | 143.00 |
| Total Revenue (TTM) | $1.31T |
| Gross Profit (TTM) | $1.00T |
| EBITDA (TTM) | $276.65B |
| Year Range | $9.35 - $13.14 |
| Target Price | $12.40 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Astellas Pharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Astellas Pharma Inc had a return of -4.34% year-to-date (YTD) and -11.06% in the last 12 months. Over the past 10 years, Astellas Pharma Inc had an annualized return of -0.37%, while the S&P 500 had an annualized return of 11.99%, indicating that Astellas Pharma Inc did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -4.34% | 22.49% |
| 1 month | -5.77% | 3.72% |
| 6 months | 20.65% | 16.33% |
| 1 year | -11.06% | 33.60% |
| 5 years (annualized) | -5.31% | 14.41% |
| 10 years (annualized) | -0.37% | 11.99% |
Monthly Returns
The table below presents the monthly returns of ALPMY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.32% | -6.50% | -2.69% | -11.06% | 2.72% | 0.51% | 17.75% | 6.89% | -7.74% | -4.34% | |||
| 2023 | -3.29% | -4.20% | 0.43% | 6.31% | 5.05% | -5.90% | -1.51% | 3.88% | -8.63% | -9.73% | -3.08% | -1.64% | -21.36% |
| 2022 | -1.13% | 3.72% | -5.48% | -3.04% | 5.02% | -2.90% | 0.33% | -8.34% | -7.49% | 3.96% | 10.76% | -0.28% | -6.38% |
| 2021 | 4.71% | -2.81% | -0.75% | -2.56% | 6.66% | 8.88% | -9.09% | 6.68% | -1.01% | 1.80% | -6.78% | 3.64% | 7.92% |
| 2020 | 4.59% | -12.48% | -0.46% | 7.93% | 6.38% | -6.14% | -6.44% | 0.58% | -4.14% | -7.56% | 3.64% | 8.52% | -7.91% |
| 2019 | 15.77% | 4.39% | -1.82% | -9.58% | -0.58% | 5.77% | 0.43% | -3.08% | 3.98% | 20.76% | -0.81% | 0.90% | 38.01% |
| 2018 | 3.42% | 12.28% | 3.71% | -3.44% | 4.42% | -0.47% | 6.47% | 4.54% | 3.81% | -11.29% | -0.76% | -16.85% | 2.22% |
| 2017 | -3.42% | 0.52% | -1.56% | 0.11% | -3.98% | -3.27% | 4.17% | -1.36% | 2.47% | 4.40% | -4.01% | 0.10% | -6.14% |
| 2016 | -5.31% | 5.57% | -6.44% | 5.08% | -2.24% | 14.02% | 7.71% | -9.04% | 2.64% | -4.49% | -6.59% | 0.42% | -1.31% |
| 2015 | 10.72% | 2.10% | 4.00% | -4.78% | -6.53% | -2.31% | 5.64% | -1.43% | -12.30% | 13.38% | -3.86% | 2.36% | 4.15% |
| 2014 | 5.84% | 2.98% | -6.91% | -6.35% | 15.14% | 2.52% | 4.73% | 4.80% | 4.08% | 1.80% | -5.09% | -2.20% | 21.06% |
| 2013 | 13.82% | 6.46% | 0.33% | 8.16% | -11.02% | 4.76% | -1.62% | -3.96% | 0.64% | 9.22% | 6.55% | -0.03% | 35.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ALPMY is 23, indicating that it is in the bottom 23% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Astellas Pharma Inc granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.41 | $0.39 | $0.36 | $0.33 | $0.31 | $0.30 | $0.26 | $0.26 | $0.26 |
Dividend yield | 0.00% | 0.00% | 0.00% | 2.54% | 2.51% | 2.09% | 2.59% | 2.45% | 2.17% | 1.81% | 1.82% | 2.19% |
Monthly Dividends
The table displays the monthly dividend distributions for Astellas Pharma Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.19 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.41 |
| 2020 | $0.00 | $0.00 | $0.19 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.20 | $0.00 | $0.00 | $0.00 | $0.39 |
| 2019 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.00 | $0.36 |
| 2018 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.17 | $0.00 | $0.00 | $0.00 | $0.33 |
| 2017 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.00 | $0.31 |
| 2016 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.00 | $0.30 |
| 2015 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.26 |
| 2014 | $0.00 | $0.00 | $0.14 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.26 |
| 2013 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.26 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Astellas Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Astellas Pharma Inc was 47.76%, occurring on Apr 15, 2024. The portfolio has not yet recovered.
The current Astellas Pharma Inc drawdown is 36.22%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -47.76% | Jun 29, 2021 | 703 | Apr 15, 2024 | — | — | — |
| -29.72% | Aug 2, 2016 | 241 | Jul 18, 2017 | 266 | Aug 8, 2018 | 507 |
| -28.67% | Sep 21, 2018 | 66 | Dec 26, 2018 | 235 | Dec 2, 2019 | 301 |
| -27.97% | Feb 10, 2020 | 30 | Mar 23, 2020 | 48 | Jun 1, 2020 | 78 |
| -25.14% | Jan 28, 2009 | 28 | Mar 12, 2009 | 86 | Aug 4, 2009 | 114 |
Volatility
Volatility Chart
The current Astellas Pharma Inc volatility is 5.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Astellas Pharma Inc compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for ALPMY in comparison to other companies of the Drug Manufacturers - General industry. Currently, ALPMY has a PE value of 143.0. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for ALPMY in comparison to other companies of the Drug Manufacturers - General industry. Currently, ALPMY has a PEG value of 0.0. This PEG value is considered to be low compared to the rest of the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Astellas Pharma Inc.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |